Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

The therapeutic effect of mesenchymal stem cells in diabetic kidney disease

Habiba UE., Khan N., Greene DL., Shamim S., Umer A.

Clinical Trial on Chronic Kidney Disease, Chronic Inflammation, published in J Mol Med (Berl) (2024) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
J Mol Med (Berl) (2024)
Reported sample size
—
Source database
Europe PMC
PMID
38418620
PMCID
PMC10963471
DOI
10.1007/s00109-024-02432-w
Citations
19

Abstract (original English)

Diabetes mellitus (DM) often causes chronic kidney damage despite best medical practices. Diabetic kidney disease (DKD) arises from a complex interaction of factors within the kidney and the whole body. Targeting specific disease-causing agents using drugs has not been effective in treating DKD. However, stem cell therapies offer a promising alternative by addressing multiple disease pathways and promoting kidney regeneration. Mesenchymal stem cells (MSCs) offer great promise due to their superior accessibility ratio from adult tissues and remarkable modes of action, such as the production of paracrine anti-inflammatory and cytoprotective substances. This review critically evaluates the development of MSC treatment for DKD as it moves closer to clinical application. Results from animal models suggest that systemic MSC infusion may positively impact DKD progression. However, few registered and completed clinical trials exist, and whether the treatments are effective in humans is still being determined. Significant knowledge gaps and research opportunities exist, including establishing the ideal source, dose, and timing of MSC delivery, better understanding of in vivo mechanisms, and developing quantitative indicators to obtain a more significant therapeutic response. This paper reviews recent literature on using MSCs in preclinical and clinical trials in DKD. Potent biomarkers r

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
KidneyMesenchymal Stem CellsAnimalsHumansDiabetic NephropathiesDiabetes MellitusAnti-Inflammatory AgentsMesenchymal Stem Cell TransplantationRegenerationAdult

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research